This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignees: Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts, Ruprecht-Karls-Universitaet Heidelberg. Active years: 2018.
Company Filing History:
1 out of 20 
1 out of 23 
Years Active: 2018
Title: Ute Koch: Innovator in Oncolytic Virotherapy
Introduction
Ute Koch is a notable inventor based in Epalinges, Switzerland. She has made significant contributions to the field of oncolytic virotherapy, particularly in the prevention of tumor recurrence. Her innovative work focuses on utilizing a parvovirus to prevent the recurrence of malignant tumors, such as brain and pancreatic tumors.
Latest Patents
Ute Koch holds 1 patent for her groundbreaking invention titled "Oncolytic virotherapy for prevention of tumor recurrence." This patent describes a novel approach using a parvovirus specifically designed to combat the recurrence of tumors, showcasing her commitment to advancing cancer treatment.
Career Highlights
Throughout her career, Ute Koch has been associated with prestigious institutions, including the Deutsches Krebsforschungszentrum (German Cancer Research Center) and Ruprecht-Karls-Universität Heidelberg. Her work in these organizations has allowed her to contribute to significant advancements in cancer research and treatment methodologies.
Collaborations
Ute Koch has collaborated with esteemed colleagues, including Irina Kiprijanova and Jean Rommelaere. These partnerships have enriched her research and expanded the impact of her innovative work in the field of oncology.
Conclusion
Ute Koch's contributions to oncolytic virotherapy represent a significant advancement in cancer treatment, particularly in preventing tumor recurrence. Her innovative approach and dedication to research continue to inspire advancements in the medical field.